Cost-effectiveness

When the INTERCEPT™ Blood System for red blood cells becomes available in the near future, blood centres will be able to implement a complete pathogen inactivation (PI) system that covers the three main labile blood components (Platelets-Plasma-RBC). The adoption of pathogen inactivation for all three components offers the potential for numerous cost-saving initiatives. The INTERCEPT Blood System for red blood cells is currently under development.